GlassScriptPhysician profile
Jerin D Bryant
NPI 1881881274
$6,432.11
in general payments reported to CMS, 2019-2025
31 companies · $889 in 2025
The $889 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,537 · 2022: $1,235 · 2023: $1,401 · 2024: $1,370 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,486 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,486.21 |
| Education | $174.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,246.38 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,163.04 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $671.99 | 2021-2024 | Myrbetriq, Veozah |
| Astrazeneca Pharmaceuticals LP | $574.35 | 2021-2025 | Farxiga, Breztri, Lokelma |
| Abbvie INC. | $368.30 | 2021-2024 | |
| Glaxosmithkline, LLC. | $227.51 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $224.18 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $212.99 | 2021-2023 | |
| Amgen INC. | $193.96 | 2021-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.35 | 2021-2025 | Jardiance |
| Inspire Medical Systems, INC. | $168.84 | 2023-2024 | Inspire |
| Amarin Pharma, INC. | $151.95 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.48 | 2021 | |
| Exact Sciences Corporation | $104.22 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.10 | 2021-2025 | Xifaxan, Trulance |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $93.66 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $89.16 | 2021-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $74.14 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $67.03 | 2024-2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $54.08 | 2022-2023 | Quviviq |
| Esperion Therapeutics, INC. | $43.63 | 2021-2024 | Nexletol |
| Shield Therapeutics INC | $43.33 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $41.35 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $41.28 | 2021 | |
| Abbott Laboratories | $38.37 | 2024 | Proclaim, Eterna |
| Dexcom, INC. | $36.36 | 2023-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $35.60 | 2021-2024 | |
| Alk-Abello, INC | $20.03 | 2024 | Ragwitek, Odactra, Grastek |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.15 | 2025 | Caplyta |
| Cumberland Pharmaceuticals, INC. | $14.25 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerin Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.